Second mutation in PARK2 is absent in patients with sporadic Parkinson's disease and heterozygous exonic deletions/duplications in parkin gene

被引:7
|
作者
Shulskaya, Marina V. [1 ]
Shadrina, Maria I. [1 ]
Fedotova, Ekaterina Yu. [2 ]
Abramycheva, Nataliya Yu. [2 ]
Limborska, Svetlana A. [1 ]
Illarioshkin, Sergey N. [2 ]
Slominsky, Petr A. [1 ]
机构
[1] Russian Acad Sci, Inst Mol Genet, Dept Mol Basics Human Genet, Moscow, Russia
[2] Fed State Sci Inst, Dept Neurogenet, Sci Ctr Neurol, Moscow, Russia
基金
俄罗斯科学基金会; 俄罗斯基础研究基金会;
关键词
Parkinson's disease; PARK2; point mutations; exon rearrangements; EARLY-ONSET PARKINSONISM; COPY NUMBER VARIATIONS; CARRIERS; DOSAGE; PINK1; SUSCEPTIBILITY; VARIANTS; COHORT; COMMON; LRRK2;
D O I
10.1080/00207454.2016.1255612
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Aim of the study: Mutations in PARK2 are one of the causes of Parkinson's disease (PD). Deletions and duplications/triplications of one exon or exon groups account for a large proportion of mutations in the gene. At the present time, it is still not fully clear whether heterozygous mutations cause the development of PD. Our study aimed at conducting screening for mutations in PARK2 in patients with a sporadic form of PD to clarify the role of PARK2 in the development of PD. Materials and methods: The cohort of 327 patients with PD was screened by quantitative real-time polimerase chain reaction (PCR) with subsequent Sanger sequencing. Results: It was found that a sufficiently large proportion of these patients (21 patients, 6.4%) were carriers of heterozygous deletions or duplications in PARK2. Analysis of PARK2 exon rearrangement carriers for the presence of point mutations in PARK2 did not reveal any variants with pathogenic significance. Conclusions: Thus, our data indicate that heterozygous deletions and duplications can play an important role in the pathogenesis of PD and can be considered as dominant mutations with low penetrance.
引用
收藏
页码:781 / 784
页数:4
相关论文
共 50 条
  • [21] Analysis of Deletion Mutations in the PARK2 Gene in Idiopathic Parkinson's Disease
    P. A. Slominsky
    O. V. Miloserdova
    S. N. Popova
    I. R. Gilyazova
    I. V. Khidiyatova
    R. V. Magzhanov
    E. K. Khusnutdinova
    S. A. Limborska
    Russian Journal of Genetics, 2003, 39 : 166 - 171
  • [22] Novel compound heterozygous mutations in the PARK2 gene identified in a Chinese pedigree with early-onset Parkinson's disease
    Shi, Yingying
    Kawakami, Hideshi
    Zang, Weizhou
    Li, Gang
    Zhang, Jiewen
    Xu, Changshui
    BRAIN AND BEHAVIOR, 2018, 8 (01):
  • [23] Event-related potential changes due to early-onset Parkinson's disease in parkin (PARK2) gene mutation carriers and non-carriers
    Uslu, Atilla
    Ergen, Mehmet
    Demirci, Hasan
    Lohmann, Ebba
    Hanagasi, Hasmet
    Demiralp, Tamer
    CLINICAL NEUROPHYSIOLOGY, 2020, 131 (07) : 1444 - 1452
  • [24] Cytogenetic study and compared with measurements of oxidative stress and PARK2 gene in Parkinson's disease patients
    Balachandar, Vellingiri
    Sureshkumar, Shanmugam
    Balamuralikrishnan, Balasubramanian
    Mohanadevi, Subramaniam
    Shantkriti, Srinivasalu
    Younis, Atta Mohd
    Dharwadkar, Shanwaz
    Sasikala, Keshavarao
    MOVEMENT DISORDERS, 2014, 29 : S83 - S83
  • [25] Prevalence of Parkin gene mutations and deletions in idiopathic Parkinson's disease
    Sinha, R
    Racette, B
    Perlmutter, JS
    Parsian, A
    MOVEMENT DISORDERS, 2002, 17 : S130 - S130
  • [26] PARK2 mutations in patients with carly-onset Parkinson's disease
    Pchelina, S
    Ivanova, O
    Hanina, N
    Yakimovsky, A
    Schwarzman, A
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2005, 238 : S367 - S367
  • [27] The PARK2 mutations in Polish early onset Parkinson's disease patients
    Koziorowski, D.
    Hoffman-Zacharska, D.
    Magdalena, N.
    Jaroslaw, S.
    Andrzej, F.
    MOVEMENT DISORDERS, 2008, 23 (01) : S52 - S52
  • [28] Bioenergetic impairment in Italian Parkinson's disease patients with PARK2 mutations
    Amati, F.
    Martino, N. A.
    Gnoni, A.
    Trentadue, R.
    Criscuolo, C.
    De Michele, G.
    Dell'Aquila, M. E.
    Papa, S.
    Sardanelli, A. M.
    FEBS JOURNAL, 2012, 279 : 387 - 387
  • [29] Parkinson's disease with Lewy bodies associated with a heterozygous PARKIN dosage mutation
    Sharp, Madeleine E.
    Marder, Karen S.
    Cote, Lucien
    Clark, Lorraine N.
    Nichols, William C.
    Vonsattel, Jean-Paul
    Alcalay, Roy N.
    MOVEMENT DISORDERS, 2014, 29 (04) : 566 - 568
  • [30] Analysis of the PARK2 Gene Exon Rearrangements and the SNCA Gene Multiplications in Patients with Parkinson's Disease from Russia
    Semenova, E. V.
    Slominsky, P. A.
    Bagyeva, G. K. H.
    Illarioshkin, S. N.
    Shadrina, M. I.
    MOVEMENT DISORDERS, 2010, 25 : S617 - S617